Table 3.
Sensitivity analysis: incremental cost-effectiveness ratio (ICER) of HPV vaccination* in Estonia, model estimates.
| ICER € per QALYs | |
|---|---|
| Base case |
4889 |
|
Screening characteristics |
|
| Under hypothetical improved cervical screening program** |
6167 |
|
Vaccine characteristics |
|
| Assuming no HPV 6/11 protection |
5771 |
| Duration of protection = 20 years |
8090 |
|
Vaccination characteristics |
|
| Low vaccine coverage (70%) |
4444 |
| High vaccine coverage (95%) |
5212 |
|
Costs characteristics |
|
| Cost of diagnosis and treatment +20% |
4744 |
| Cost of diagnosis and treatment −20% |
5037 |
| Cost of vaccine - 10% |
4351 |
| Cost of vaccine + 10% |
5454 |
|
Health utility values |
|
| Cost per life year saved (no quality of life adjustments) |
6746 |
|
Discount rate |
|
| Discount rate 0% |
1517 |
| Discount rate 5% | 11148 |
* HPV6/11/16/18 related cervical cancer and genital warts.
**Vaccination program introduced alongside hypothetical improved cervical screening program.